[Intervention with clarithromycin in patients with stable coronary heart disease--the CLARICOR trial: secondary publication]
- PMID: 17303029
[Intervention with clarithromycin in patients with stable coronary heart disease--the CLARICOR trial: secondary publication]
Abstract
Antibiotics may reduce cardiovascular morbidity. We randomised 4372 patients with stable coronary heart disease in the CLARICOR trial to clarithromycin 500 mg (n = 2172) or placebo (n = 2200) daily for a fortnight. After 2.6 years we found significantly increased cardiovascular mortality among the clarithromycin patients. There is a need for studies to evaluate the safety of clarithromycin. There is presently no evidence to support the preventive effect of antibiotics on patients with coronary heart disease.
Republished from
-
Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial.BMJ. 2006 Jan 7;332(7532):22-7. doi: 10.1136/bmj.38666.653600.55. Epub 2005 Dec 8. BMJ. 2006. PMID: 16339220 Free PMC article. Clinical Trial.